Tiziana Life Sciences Ltd TLSA
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 2.47M | 2.47M | 2.46M | 2.46M | 2.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 5.69M | 5.69M | 5.97M | 5.97M | 4.59M |
| Operating Income | -5.69M | -5.69M | -5.97M | -5.97M | -4.59M |
| Income Before Tax | -6.19M | -6.19M | -6.40M | -6.40M | -2.82M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -6.19M | -6.19M | -6.40M | -6.40M | -2.82M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -6.19M | -6.19M | -6.40M | -6.40M | -2.82M |
| EBIT | -5.69M | -5.69M | -5.97M | -5.97M | -4.59M |
| EBITDA | -5.68M | -5.68M | -5.97M | -5.97M | -4.59M |
| EPS Basic | -0.05 | -0.05 | -0.05 | -0.05 | -0.02 |
| Normalized Basic EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| EPS Diluted | -0.05 | -0.05 | -0.05 | -0.05 | -0.02 |
| Normalized Diluted EPS | -0.03 | -0.03 | -0.03 | -0.03 | -0.02 |
| Average Basic Shares Outstanding | 127.87M | 127.87M | 119.74M | 119.74M | 116.83M |
| Average Diluted Shares Outstanding | 127.87M | 127.87M | 119.74M | 119.74M | 116.83M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |